Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2026
Business Overview: BMS operates as a single segment focused on the discovery, development, and commercialization of innovative medicines for serious diseases, primarily in oncology, hematology, immunology, cardiovascular, and neuroscience.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $11,489 | $11,201 |
| Net Earnings Attributable to BMS | $2,677 | $2,456 |
| Diluted EPS (GAAP) | $1.31 | $1.20 |
| Diluted EPS (Non-GAAP) | $1.58 | $1.80 |
| Operating Cash Flow | $1,104 | $1,954 |
| Free Cash Flow (Approx.) | $757 | $1,694 |
| Total Debt (Short + Long Term) | $44,460 | $45,111 |
| Cash & Cash Equivalents | $9,574 | $10,209 |
| Effective Tax Rate | 17.3% | 17.1% |
Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($347 million).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 3% year-over-year. Growth was driven by the Growth Portfolio (+12%) and Eliquis (+16%), partially offset by declines in the Legacy Portfolio (-6%) due to generic erosion (Revlimid, Pomalyst, Sprycel, Abraxane).
- Profitability: GAAP Net Earnings increased 9% to $2.677 billion. This was primarily due to a $393 million decrease in amortization of acquired intangible assets (Pomalyst fully amortized in Q4 2025), partially offset by $410 million in IPRD impairment charges and the expiration of diabetes royalty income.
- Non-GAAP Performance: Non-GAAP EPS decreased $0.22 to $1.58, primarily due to the loss of royalty income from the terminated diabetes business agreement with AstraZeneca.
- Operating Cash Flow: Decreased $850 million to $1.104 billion, driven by lower net customer receipts (due to Eliquis list price reductions) and higher litigation-related disbursements.
- Debt Reduction: Net debt position improved by $436 million to $33.607 billion, aided by operating cash flows and equity investment sales, offset by $1.283 billion in dividend payments and $500 million in debt repayments.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Pipeline Progress: Significant positive developments include Phase III results for mezigdomide (RRMM), Camzyos (adolescents with oHCM), and iza-bren (TNBC). FDA accepted an NDA for iberdomide (RRMM) with a PDUFA date of August 17, 2026.
- Strategic Initiatives: BMS expects to realize annual cost savings of approximately $2.0 billion by the end of 2027 through its ongoing strategic productivity initiative.
- Government Agreements: Under a December 2025 U.S. Government Agreement, BMS agreed to provide Eliquis for free to Medicaid and offer significant discounts on other products. In exchange, BMS received tariff relief until January 2029 and exemption from future U.S. pricing mandates while the agreement is in effect.
Risks and Contingencies
- Patent Litigation: Ongoing challenges to Eliquis patents in Europe and the U.S. (Azurity Pharmaceuticals). Generics have entered markets in the UK, Poland, and other EU countries.
- Regulatory Pricing: The Inflation Reduction Act (IRA) has set "maximum fair prices" for Eliquis (effective Jan 2026) and Pomalyst (effective Jan 2027). Orencia was selected for price negotiation starting in 2028.
- Legal Proceedings: Active litigation includes the Celgene Securities Class Action (settlement pending final approval), Contingent Value Rights (CVR) lawsuits regarding Breyanzi milestones, and pricing/promotional practices litigation (Plavix Texas case).
- Impairments: Recorded $410 million in IPRD impairment charges related to a radiopharmaceutical asset and an oncology asset.
Investor Verification Checklist
- Eliquis Pricing Impact: Verify the actual revenue impact of the IRA "maximum fair price" and the U.S. Government Agreement (free Eliquis for Medicaid) on future quarters.
- Generic Erosion: Monitor the rate of revenue decline in the Legacy Portfolio (Revlimid, Pomalyst, Sprycel) as generic competition expands in the U.S. and EU.
- IPRD Impairments: Assess the likelihood of further impairment charges given the $410 million write-down in Q1 2026 and the competitive landscape in oncology.
- Cash Flow Sustainability: Review the trend in operating cash flows, which dropped significantly due to receivables management and litigation costs, to ensure sufficiency for dividends and R&D.
- Legal Resolutions: Track the final approval of the Celgene Securities settlement and the outcome of the CVR litigation, which could result in significant liabilities.